Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): A Randomized, Double-Blind, Placebo-Controlled Trial
Leronlimab resulted in significantly reduced plasma HIV-1 within 1 week after addition to failing antiretroviral therapy. After 24 weeks combined with an optimized background treatment, most participants had plasma HIV-1 RNA levels <50 copies per milliliter plasma, suggesting utility of leronlimab as a component of salvage therapy.
Authors
- Jacob Lalezari (ORCID: https://orcid.org/0000-0002-2744-4918)
- Alok Krishen
- Jonah B. Sacha (ORCID: https://orcid.org/0000-0002-7633-3122)
- Charlotte-Paige Rolle (ORCID: https://orcid.org/0000-0002-6444-2225)
- Scott G. Hansen (ORCID: https://orcid.org/0000-0002-9845-6481)
- Otto O. Yang (ORCID: https://orcid.org/0000-0003-1970-8992)
- Edwin DeJesus
- Moti N. Ramgopal (ORCID: https://orcid.org/0000-0001-7448-1976)
- William E. Sanchez
- Joseph Gathe
- Joseph Meidling
Institutions
- Oregon National Primate Research Center (US)
- Midway University (US)
- University of California, Los Angeles (US)
- Oregon Health & Science University (US)
- Floridian Research Institute (US)
- Quest Clinical Research (United States) (US)
- Cytodiagnostics (Canada) (CA)
- Université Bourgogne Franche-Comté (FR)
- Orlando Immunology Center (US)
Publication Details
- Journal
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1097/qai.0000000000003648
- Citations
- 4
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.58